Stock DIAMYD MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Diamyd Medical AB Share Price Swiss Exchange

Equities

SE0005162880

Biotechnology & Medical Research

End-of-day quote Swiss Exchange
Other stock markets
- SEK - Intraday chart for Diamyd Medical AB
05-16 Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI
04-18 Diamyd Medical Raises SEK57 Million in Rights Issue MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 3M 284K 22.46M Sales 2025 * 3M 284K 22.46M Capitalization 1.41B 133M 10.53B
Net income 2024 * -133M -12.61M -996M Net income 2025 * -165M -15.64M -1.24B EV / Sales 2024 * 422 x
Net cash position 2024 * 139M 13.18M 1.04B Net cash position 2025 * 30M 2.84M 225M EV / Sales 2025 * 459 x
P/E ratio 2024 *
-10.6 x
P/E ratio 2025 *
-8.55 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.2%
More Fundamentals * Assessed data

Latest news about Diamyd Medical AB

Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI
Diamyd Medical Raises SEK57 Million in Rights Issue MT
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial CI
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Diamyd Medical to Raise SEK114 Million Via Share Offering MT
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment MT
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production CI
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024 CI
Certain B Shares of Diamyd Medical AB are subject to a Lock-Up Agreement Ending on 27-DEC-2023. CI
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea CI
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board CI
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial MT
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial CI
More news

Latest transcript on Diamyd Medical AB

Logo Diamyd Medical AB
Diamyd Medical AB - Special Call
More transcripts

Press releases Diamyd Medical AB

Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment AQ
Diamyd Medical announces final outcome in the company's rights issue AQ
Diamyd Medical announces preliminary outcome in the company's rights issue AQ
Recruitment milestone reached in Diamyd® Phase 3 trial AQ
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes AQ
More press releases

Managers and Directors - Diamyd Medical AB

Managers TitleAgeSince
Ulf Hannelius CEO
 Chief Executive Officer 49 09/04/16
Anders Essen-Möller FOU
 Founder 83 31/12/95
Anna Styrud DFI
 Director of Finance/CFO 63 31/12/09
Members of the board TitleAgeSince
Anders Essen-Möller FOU
 Founder 83 31/12/95
Erik Kjellsson Nerpin BRD
 Director/Board Member 63 31/12/11
Karin Hehenberger BRD
 Director/Board Member 52 27/04/21
More insiders

Company Profile

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Sector
Biotechnology & Medical Research
Calendar
25/06/2024 - Q3 2024 Earnings Release
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
ARGENX SE Stock argenx SE
+4.31% 22.94B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
GENMAB A/S Stock Genmab A/S
-16.47% 16.88B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
INSMED INCORPORATED Stock Insmed Incorporated
+106.26% 10.31B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DMYD B Stock
  4. Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW